Founded in 2020, AcadeMab Biomedical Inc. (hereinafter shortened as AM) is a start-up company dedicated to the development of new antibody drugs in the medical field that requires urgent breakthroughs. As cancer is widely acknowledged as a leading cause of death across the globe, we take it upon ourselves to research on the cancer therapy as our first step. From there, we expanded to other life-threaten diseases in different fields. To this end, we have developed multiple in-house technology platforms to break fresh ground for new antibody drugs. Our mission is to improve life quality and human health by providing the first-in-class or best-in-class new antibody drugs.
AcadeMab Biomedical Inc’s story begins at the Institute of Cellular and Organismic Biology (ICOB), Academia Sinica where Dr. Han-Chung Wu works as a Distinguished Research Fellow. Dr. Wu has made significant breakthroughs that could lead to the much-anticipated ultimate cancer cure in animal models. His research findings on the epithelial cell adhesion molecule (EpCAM) antibody won him the Germination Program funding from Taiwan’s Ministry of Science and Technology (MOST) in November 2019. With MOST’s funding, Dr. Wu has embarked on the path of commercializing his antibody study results and founded AcadeMab Biomedical Inc. In 2020, AM set up a base at the National Biotechnology Research Park in Nangang.